

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

April 29, 2024

Francois Michelon Chief Executive Officer ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105-1570

> Re: ENDRA Life Sciences Inc. Registration Statement on Form S-1 Filed April 19, 2024 File No. 333-278842

Dear François Michelon:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Nicholas O'Leary at 202-551-4451 with any questions.

Sincerely,

Division of Corporation Finance Office of Industrial Applications and Services

cc: Coleman Wombwell, Esq.